Initiation of buprenorphine during incarceration and retention in treatment upon release

Journal of Substance Abuse Treatment

Volumn 45, Issue 2, 2013, Pages 222-226

  Zaller, Nickolas ^a,b   McKenzie, Michelle ^a,b   Friedmann, Peter D ^b,c   Green, Traci C ^b,c   McGowan, Samuel ^a   Rich, Josiah D ^a,b  

^a MIRIAM HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Addiction; Buprenorphine naloxone; HIV; Incarceration; Opiates

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMMUNITY CARE; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PRESCRIPTION; PRIORITY JOURNAL; PRISONER; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; BUPRENORPHINE; COMMUNITY HEALTH SERVICES; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NALOXONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PILOT PROJECTS; PRISONERS; RHODE ISLAND; TIME FACTORS;

EID: 84879145218     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2013.02.005     Document Type: Article

References (36)

1. Alford D.P., LaBelle C.T., Kretsch N., Bergeron A., Winter M., Botticelli M., et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine. Archives of Internal Medicine 2011, 171:425-431.
2. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence 2007, 88:75-78. 10.1016/j.drugalcdep.2006.09.012.
3. Auriacombe M., Fatseas M., Dubernet J., Daulouede J.P., Tignol J. French field experience with buprenorphine. The American Journal on Addictions 2004, 13(Suppl 1):S17-S28. 10.1080/10550490490440780.
4. Auriacombe M., Franques P., Tignol J. Deaths attributable to methadone vs buprenorphine in France. Journal of the American Medical Association 2001, 285:45-51. [United States].
5. Awgu E., Magura S., Rosenblum A. Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance. Journal of Psychoactive Drugs 2010, 42:339-346.
6. Baker A., Kochan N., Dixon J., Wodak A., Heather N. HIV risk-taking behaviour among injecting drug users currently, previously and never enrolled in methadone treatment. Addiction 1995, 90:545-554.
7. Bazazi A.R., Yokell M., Fu J.J., Rich J.D., Zaller N.D. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. Journal of Addictive Medicine 2011, 5:175-180. 10.1097/ADM.0b013e3182034e31.
8. Binswanger I.A., Stern M.F., Deyo R.A., Heagerty P.J., Cheadle A., Elmore J.G., et al. Release from prison-A high risk of death for former inmates. The New England Journal of Medicine 2007, 356:157-165. 10.1056/NEJMsa064115.
9. Carrieri M.P., Amass L., Lucas G.M., Vlahov D., Wodak A., Woody G.E. Buprenorphine use: The international experience. Clinical Infectious Diseases 2006, 43(Suppl 4):S197-S215. 10.1086/508184.
10. Cropsey K.L., Lane P.S., Hale G.J., Jackson D.O., Clark C.B., Ingersoll K.S., et al. Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. Drug and Alcohol Dependence 2011, 119:172-178. 10.1016/j.drugalcdep.2011.06.021.
11. Dasgupta N., Bailey E.J., Cicero T., Inciardi J., Parrino M., Rosenblum A., et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Medicine 2010, 11:1078-1091. 10.1111/j.1526-4637.2010.00877.x.
12. Fhima A., Henrion R., Lowenstein W., Charpak Y. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex). Ann Med Interne (Paris) 2001, 152(Suppl 3):IS26-IS36.
13. Fiellin D.A., Rosenheck R.A., Kosten T.R. Office-based treatment for opioid dependence: Reaching new patient populations. The American Journal of Psychiatry 2001, 158:1200-1204.
14. Garcia C.A., Correa G.C., Viver A.D., Kinlock T.W., Gordon M.S., Avila C.A., et al. Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. Journal of Addictive Medicine 2007, 1:126-132. 10.1097/ADM.0b013e31814b8880.
15. Gordon M.S., Kinlock T.W., Miller P.M. Medication-assisted treatment research with criminal justice populations: Challenges of implementation. Behavioral Sciences & the Law 2011, 29:829-845. 10.1002/bsl.1015.
16. Gore S.M., Bird A.G., Ross A.J. Prison rites: Starting to inject inside. BMJ 1995, 311:1135-1136.
17. Hammett T.M. HIV/AIDS and other infectious diseases among correctional inmates: Transmission, burden, and an appropriate response. American Journal of Public Health 2006, 96:974-978. [United States].
18. Inciardi J.A., Needle R.H. Editors' introduction: HIV/AIDS interventions for out-of-treatment drug users. Journal of Psychoactive Drugs 1998, 30:225-229.
19. Johanson C.E., Arfken C.L., di Menza S., Schuster C.R. Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug and Alcohol Dependence 2012, 120:190-195. 10.1016/j.drugalcdep.2011.07.019.
20. Johnson R.E., Strain E.C., Amass L. Buprenorphine: How to use it right. Drug and Alcohol Dependence 2003, 70(2 Suppl):S59-S77.
21. Kinlock T.W., Gordon M.S., Schwartz R.P., Fitzgerald T.T. Developing and implementing a new prison-based buprenorphine treatment program. J Offender Rehabil 2010, 49:91-109. 10.1080/10509670903534951.
22. Lee J.D., Grossman E., Truncali A., Rotrosen J., Rosenblum A., Magura S., et al. Buprenorphine-naloxone maintenance following release from jail. Substance Abuse 2012, 33:40-47. 10.1080/08897077.2011.620475.
23. Lipton D.S., Falkin G.P., Wexler H.K. Correctional drug abuse treatment in the United States: An overview. NIDA Research Monograph 1992, 118:8-30.
24. Magura S., Lee J.D., Hershberger J., Joseph H., Marsch L., Shropshire C., et al. Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug and Alcohol Dependence 2009, 99:222-230. 10.1016/j.drugalcdep.2008.08.006.
25. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, CD002207.
26. McKenzie M., Zaller N., Dickman S.L., Green T.C., Parihk A., Friedmann P.D., et al. A randomized trial of methadone initiation prior to release from incarceration. Substance Abuse 2012, 33:19-29. 10.1080/08897077.2011.609446.
27. McLellan A.T., Alterman A.I., Cacciola J., Metzger D., O'Brien C.P. A new measure of substance abuse treatment. Initial studies of the treatment services review. Journal of Nervous and Mental Disease 1992, 180:101-110.
28. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992, 9:199-213.
29. Nunn A., Zaller N., Dickman S., Trimbur C., Nijhawan A., Rich J.D. Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug and Alcohol Dependence 2009, 105:83-88. 10.1016/j.drugalcdep.2009.06.015.
30. Rhode Island Department of Corrections Population Report FY2011: State of Rhode Island 2011, http://www.doc.ri.gov/administration/planning/statistics_reports.php.
31. Rich J.D., Boutwell A.E., Shield D.C., Key R.G., McKenzie M., Clarke J.G., et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. Journal of Urban Health 2005, 82:411-419. 10.1093/jurban/jti072.
32. Rich J.D., McKenzie M., Dickman S., Bratberg J., Lee J.D., Schwartz R.P. An adverse reaction to buprenorphine/naloxone induction in prison: A case report. Addict Disord Their Treat 2011, 10:199-200. 10.1097/ADT.0b013e3182133949.
33. Sabol W., West H., Cooper M. Prisoners in 2008 2010, Bureau of Justice Statistics: U.S. Department of Justice, Washington D.C.
34. Schuman-Olivier Z., Albanese M., Nelson S.E., Roland L., Puopolo F., Klinker L., et al. Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. Journal of Substance Abuse Treatment 2010, 39:41-50. 10.1016/j.jsat.2010.03.014.
35. Yokell M.A., Zaller N.D., Green T.C., Rich J.D. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Current Drug Abuse Reviews 2011, 4:28-41.
36. Zaller N.D., Bazazi A.R., Velazquez L., Rich J.D. Attitudes toward methadone among out-of-treatment minority injection drug users: Implications for health disparities. International Journal of Environmental Research and Public Health 2009, 6:787-797. 10.3390/ijerph6020787.